Peter Fibiger Bang

ORCID: 0000-0001-6028-0911
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Classical Antiquity Studies
  • Tuberculosis Research and Epidemiology
  • Colonialism, slavery, and trade
  • Byzantine Studies and History
  • Historical Economic and Social Studies
  • Eurasian Exchange Networks
  • Ancient Mediterranean Archaeology and History
  • Global Maritime and Colonial Histories
  • vaccines and immunoinformatics approaches
  • Islamic Studies and History
  • Immunodeficiency and Autoimmune Disorders
  • Ancient Near East History
  • Complement system in diseases
  • Archaeology and Historical Studies
  • Classical Studies and Legal History
  • Historical and Archaeological Studies
  • Balkan and Eastern European Studies
  • European and International Law Studies
  • Historical and Religious Studies of Rome
  • Historical and Linguistic Studies
  • Historical Economic and Legal Thought
  • Immunotherapy and Immune Responses
  • Soviet and Russian History
  • Immune Cell Function and Interaction
  • American Constitutional Law and Politics

Statens Serum Institut
2011-2024

University of Copenhagen
2009-2023

Sax Institute
1995-2016

Glostrup Hospital
2005

Hvidovre Hospital
2005

University of Cambridge
2003

Corpus Christi College
2002

Texas A&M University – Corpus Christi
2002

<b>Objective:</b> To investigate if IV immunoglobulin (IVIG) treatment in the acute phase of optic neuritis (ON) could improve visual outcome and reduce MRI disease activity 6 months after onset ON. <b>Methods:</b> Sixty-eight patients with ON were randomized within 4 weeks from symptoms. Thirty-four to IVIG 0.4 g/kg body wt, 34 placebo. Infusions given at days 0, 1, 2, 30, 60. Contrast sensitivity, acuity, color vision measured baseline 1 week, month, months. Pattern reversal evoked...

10.1212/01.wnl.0000152873.82631.b3 article EN Neurology 2005-03-08

Abstract Host-directed-therapy strategies are warranted to fight tuberculosis. Here we assess the safety and immunogenicity of adjunctive vaccination with H56:IC31 candidate cyclooxygenase-2-inhibitor treatment (etoricoxib) in pulmonary extra-pulmonary tuberculosis patients a randomized open-label phase I/II clinical trial (TBCOX2, NCT02503839). A total 222 were screened, 51 enrolled randomized; 13 etoricoxib-group, 14 H56:IC31-group, 12 etoricoxib+H56:IC31-group controls. Three Serious...

10.1038/s41467-021-27029-6 article EN cc-by Nature Communications 2021-11-22

Abstract Mannose‐binding lectin (MBL) is an important component of innate immunity that can bind to certain sugar residues on the surface many types pathogenic micro‐organisms. On binding, MBL generates opsonic activity mainly through activation complement system. Genetically determined deficiency very common and be associated with increased susceptibility a variety infections, especially in children immunosuppressed individuals. The potential benefits reconstitution therapy therefore need...

10.1111/j.0300-9475.2004.01357.x article EN Scandinavian Journal of Immunology 2004-01-01

The greatness of a state, and the happiness its subjects … are commonly allowed to be inseparable with regard commerce; as private men receive greater security, in possession their trade riches, from power public, so public becomes powerful proportion opulence extensive commerce men. David Hume And if our rule measuring degrees politeness civilization is taken hence, or advancement commercial arts, we shall found have greatly excelled any celebrated nations antiquity. Adam Ferguson Whatever...

10.1093/pastj/gtl031 article EN Past & Present 2007-05-01

An abstract is not available for this content so a preview has been provided. Please use the Get access link above information on how to content.

10.3815/007543509789744783 article EN The Journal of Roman Studies 2009-11-01

Background Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups, including HIV-infected individuals. In this phase II multi-centre, double-blind, placebo-controlled trial, the safety immunogenicity of novel H1/IC31 vaccine, a fusion protein Ag85B-ESAT-6 (H1) formulated with adjuvant IC31, was evaluated adults. Methods adults CD4+ T cell counts >350/mm3 without evidence active were enrolled followed until day 182. vaccine or placebo randomly...

10.1371/journal.pone.0114602 article EN cc-by PLoS ONE 2014-12-09

To estimate the clinical significance of low serum concentrations mannose-binding lectin (MBL) in patients with acute myeloid leukaemia (AML) during initial cancer chemotherapy.80 consecutive, newly diagnosed, and unselected AML (age 18-77 yr) undergoing remission induction chemotherapy. The were examined for 28 d.Low levels MBL (<1,000 microg/L) found 16/80 at diagnosis. This frequency is similar to what general population. In remaining 64 patients, significantly higher than controls showed...

10.1034/j.1600-0609.2003.00012.x article EN European Journal Of Haematology 2003-02-01
Coming Soon ...